Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia ( n = 13), B cell non-Hodgkin lymphoma ( n = 14), and multiple myeloma ( n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure. Vaccination is effective in preventing severe COVID-19 symptoms. Here the authors monitor patients with hematopoietic malignancy to find the third dose of the mRNA vaccine, BNT162b2, only boosts the humoral immunity in those showing responses to 2nd dose vaccination but can induce an independent T-cell response in a fraction of seronegative patients.
【저자키워드】 SARS-CoV-2, RNA vaccines, Haematological cancer, cellular immunity, 【초록키워드】 neutralizing antibody, antibodies, Vaccine, immune response, vaccination, mRNA vaccine, Hematological malignancy, T-cell Response, B cell, vaccine dose, BNT162b2, Humoral immunity, Cohort, Multiple myeloma, response, Patient, leukemia, boost, IFN-γ, Neutralizing antibody titer, Pfizer/BioNTech, dose, malignancy, Non-Hodgkin Lymphoma, Support, Side effect, secretion, seronegative patients, fraction, malignancies, positive, lymphoid, anti-S, immune stimulation, MONITOR, severe COVID-19 symptoms, effective, independent, reported, increase, induce, of BNT162b2, seronegative patient, the median, 【제목키워드】 Vaccine, Patient, cellular response, dose, malignancy, lymphoid, SARS-CoV-2 BNT162b2,